From Rare to Common: Genetic Insights into TLR7 Variants in a Multicentric Spanish Study on COVID-19 Severity
TLR7, which encodes a key receptor for single-stranded RNA (ssRNA) virus of the innate immune system, was recently associated with X-linked immunodeficiency and COVID-19 susceptibility. This study investigates the association between TLR7 variants and susceptibility to severe COVID-19 in a multicentric Spanish cohort. The TLR7 gene was sequenced in a cohort of 365 COVID-19 patients, stratified into two groups: one comprising mild and asymptomatic patients, considered as controls (n = 87), and the other consisting of moderate to severely affected patients hospitalized due to COVID-19 pneumonia, considered as cases (n = 278). A total of 152 unique TLR7 variants were identified, of note, six rare variants were identified in 11 cases (3.96%), all of whom belonged to the case group. The functional impact of rare TLR7 variants was assessed using a luciferase reporter assay and revealed that N215S is a loss-of-function (LOF) variant, while D332G exhibits an hypomorphic behavior. Conversely, H90Y, V219I, A448V, and R902K maintained normal signaling. No skewed X-inactivation was observed in female carriers of N215S or D332G. In addition, the common variants Q11L (rs179008), c.4-151A>G (rs179009) and c.*881C>G (rs3853839) were associated with severe pneumonia, while c.4-151A>G (rs179009) was specifically linked to Intensive Care Unit (ICU) admission. These findings highlight the role of TLR7 in antiviral immune response and its association with severe COVID-19 in men. The luciferase assay proves to be a reliable tool for evaluating TLR7 signaling, effectively distinguishing between neutral, LOF, and gain-of-function (GOF) variants. Further research is needed to better understand TLR7 variants and its implications in immunodeficiency and immune dysregulation.
Authors
- Arnau Antolí (ORCID: https://orcid.org/0000-0003-4576-1308)
- José Pablo Gómez-Vázquez (ORCID: https://orcid.org/0000-0002-6712-0029)
- Gardenia Vargas‐Parra (ORCID: https://orcid.org/0000-0003-1378-736X)
- Alexandre Pérez‐González (ORCID: https://orcid.org/0000-0003-4836-6768)
- Julen Viana-Errasti (ORCID: https://orcid.org/0000-0002-9672-6951)
- Xavier Solanich (ORCID: https://orcid.org/0000-0002-2572-2187)
- Paula Rofes (ORCID: https://orcid.org/0000-0001-6045-7879)
- Elisabet Munté (ORCID: https://orcid.org/0000-0001-8396-8284)
- Adriana López‐Doriga (ORCID: https://orcid.org/0000-0003-1352-7306)
- Eva Poveda (ORCID: https://orcid.org/0000-0003-4835-9875)
- Jesús Del Valle (ORCID: https://orcid.org/0000-0003-3607-7045)
- Lídia Feliubadaló (ORCID: https://orcid.org/0000-0002-1736-0112)
- Conxi Lázaro
- Àngels Sierra-Fortuny
- Raúl Marín-Montes
Institutions
- Instituto de Salud Carlos III (ES)
- Bellvitge University Hospital (ES)
- University Hospital Complex Of Vigo (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Hospital de Nens de Barcelona (ES)
- Galicia Sur Biomedical Foundation (ES)
- Institut Català d'Oncologia (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Journal of Clinical Immunology
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1007/s10875-025-01892-0
- Citations
- 4
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- Fundació la Marató de TV3
- Centres de Recerca de Catalunya
- Generalitat de Catalunya
- Centro de Investigación Biomédica en Red de Cáncer
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Instituto de Salud Carlos III